Evidence map›Paper›PMID 40890887›Full record

ReviewTropical medicine and health2025

Progress and challenges in tuberculosis preventive treatment in the Western Pacific Region: a situational analysis of seven high tuberculosis burden countries.

Kyung Hyun Oh, Alvin Kuo Jing Teo, Manami Yanagawa, Avinash Kanchar, Dennis Falzon, Cecily Miller, Youngeun Choi, Gyeong In Lee, Fukushi Morishita, Kalpeshsinh Rahevar and 3 more

Abstract readReview
In one paragraph

Review in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kyung Hyun OhWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines. ohk@who.int.
Alvin Kuo Jing TeoFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Manami YanagawaWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines.
Avinash KancharWorld Health Organization, Global Programme on Tuberculosis and Lung Health, Geneva, Switzerland.
Dennis FalzonWorld Health Organization, Global Programme on Tuberculosis and Lung Health, Geneva, Switzerland.
Cecily MillerWorld Health Organization, Global Programme on Tuberculosis and Lung Health, Geneva, Switzerland.
Youngeun ChoiKorean Institute of Tuberculosis, Korean National Tuberculosis Association, Cheongju, Republic of Korea.
Gyeong In LeeKorean Institute of Tuberculosis, Korean National Tuberculosis Association, Cheongju, Republic of Korea.
Fukushi MorishitaWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines.
Kalpeshsinh RahevarWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines.
Huong Thi Giang TranWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines.
Rajendra Prasad Hubraj YadavWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines.
Regional TB Consortium

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundTuberculosis preventive treatment (TPT) can avert progression from infection to disease, yet scale-up across the World Health Organization Western Pacific Region is patchy. To guide acceleration, we assessed progress, challenges and responses in seven high-burden countries-Cambodia, China, Lao People's Democratic Republic (PDR), Mongolia, Papua New Guinea, the Philippines and Viet Nam-drawing on 2015-2023 programme data, structured questionnaires, follow-up interviews and a regional validation workshop. MAIN BODY: Six of the seven countries have issued national TPT guidelines and five now offer shorter rifapentine- or rifampicin-based regimens. The number of people started on TPT rose sharply in most settings, driven by household contacts aged ≥ 5 years in Cambodia, Mongolia and the Philippines and by people living with HIV in Lao PDR and Papua New Guinea. However, coverage of children under five and other high-risk groups remains low. Cascade analysis revealed major attrition between screening and TPT initiation. Key obstacles, viewed through a socio-ecological lens, include: individual complacency, fear of adverse events and limited provider confidence; stigma and consent barriers in migrant households; intermittent staff training, medicine stock-outs and weak digital tools; long journeys to health facilities; and policy-practice gaps such as the absence of child-friendly formulations and non-notification of tuberculosis infection. Countries and partners endorsed a tiered package combining patient-centred counselling, mobile reminders, shorter paediatric regimens, stigma-reduction campaigns and remote e-consent. Health systems will reinforce staff training, digital supply-chain and adherence tools, while decentralised one-stop outreach and community health-workers extend coverage. A multisector task force will fast-track paediatric fixed-dose registration, make infection notifiable and absorb preventive treatment costs into national budgets and insurance schemes.

conclusionsThe introduction of shorter regimens and rising enrolment confirm that rapid gains are achievable, yet wide disparities persist across age groups, risk categories and care-cascade stages. Implementing the agreed client, community, institutional and policy interventions-backed by integrated governance and sustainable domestic funding-can convert TPT from a promising guideline into a routine, life-saving component of primary health care throughout the Western Pacific Region.

Indexed as

Asia and PacificTuberculosisTuberculosis preventive treatment

Identifiers

PMID40890887
PMCPMC12403340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.